Previously, a general dependency of KRAS-mutated NSCLC on XPO1 was reported, and Selinexor monotherapy reduced tumor growth in multiple patient-derived lung adenocarcinoma xenografts (94). This evidence concerns the gene XPO1 and non-small cell lung carcinoma.